Miscellaneous Malignancies | Norton Healthcare

Indication: Miscellaneous Malignancies

A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors – ARTISTRY-1

Advanced Solid Tumors

Line of Therapy: Solid Tumor, Refractory RCC, Refractory melanoma, Melanoma, 2L NSCLC, 2L SCCHN

Drug Study

Principal Investigator: Jaspreet Grewal, M.D.
Norton Cancer Institute

Sponsor: Alkermes, Inc

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.